ArticleDiabetes & metabolism journal2011
Diabetes and cancer: is diabetes causally related to cancer?
Article in Diabetes & metabolism journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.
- Standards of medical care in diabetes--2012.Diabetes care · 2012Guideline
- Multi-omics signature of healthy versus unhealthy lifestyles reveals associations with diseases.Human genomics · 2025Article
- Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2025Review
- Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Article
- Combining Sulfonylureas with Anticancer Drugs: Evidence of Synergistic Efficacy with Doxorubicin In Vitro and In Vivo.International journal of molecular sciences · 2025Article
- Mitochondrial ALDH2 improves ß-cell survival and function against doxorubicin-induced apoptosis by targeting CK2 signaling.Journal of diabetes investigation · 2024Article
- Glycemic traits and colorectal cancer survival in a cohort of South Korean patients: A Mendelian randomization analysis.Cancer medicine · 2024Article
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023.Diabetes care · 2023Review
- Influence of type II diabetes mellitus on postoperative complications following colorectal cancer surgery.Experimental and therapeutic medicine · 2022Article
- Doxorubicin-induced apoptosis enhances monocyte infiltration and adverse cardiac remodeling in diabetic animals.Canadian journal of physiology and pharmacology · 2022Article
- A Novel Metabolic Reprogramming Strategy for the Treatment of Diabetes-Associated Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Sleep Disruption and Cancer: Chicken or the Egg?Frontiers in neuroscience · 2022Review
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022.Diabetes care · 2022Review
- Metformin suppresses breast cancer growth via inhibition of cyclooxygenase-2.Oncology letters · 2021Article
- High glucose-ROS conditions enhance the progression in cholangiocarcinoma via upregulation of MAN2A2 and CHD8.Cancer science · 2021Article
- Utility ofGlobal medical genetics · 2020Review
- Cohort Profile: The Maule Cohort (MAUCO).International journal of epidemiology · 2020Article
- Site-specific cancer risk in patients with type 2 diabetes: a nationwide population-based cohort study in Korea.The Korean journal of internal medicine · 2020Article
- Glycation Leads to Increased Polysialylation and Promotes the Metastatic Potential of Neuroblastoma Cells.Cells · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a serious and growing health problem worldwide and is associated with severe acute and chronic complications. Moreover, epidemiologic evidence suggests that people with diabetes are at significantly higher risk for many forms of cancer. Several studies indicate an association between diabetes and the risk of liver, pancreas, endometrium, colon/rectum, breast, and bladder cancer. Mortality is also moderately increased in subjects with diabetes. Common risk factors such as age, obesity, physical inactivity and smoking may contribute to increased cancer risk in diabetic patients. Hyperinsulinemia most likely favors cancer in diabetic patients as insulin is a growth factor with pre-eminent metabolic as well as mitogenic effects, and its action in malignant cells is favored by mechanisms acting at both the receptor and post-receptor level. The effect of diabetes treatment drugs, aside from metformin, on cancer is not conclusive. In order to fight the perfect storm of diabetes and cancer, strategies to promote primary prevention and early detection of these conditions are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.